Please try another search
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Christine E. Siu | 46 | 2020 | Independent Director |
Jan Skvarka | 56 | 2023 | Independent Director |
Alexander Mayweg | 48 | 2018 | Non-Executive Director |
Markus Warmuth | 52 | 2020 | President, CEO & Director |
Ali Behbahani | 48 | 2020 | Independent Director |
Chandra Paul Leo | 54 | 2020 | Independent Director |
Andrew Newman Schiff | 59 | 2020 | Independent Chairman of the Board |
Anthony M. Manning | 62 | 2023 | Director |
Kimberly Lynn Blackwell | 54 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review